Head-to-head evidence
eloralintide vs MET-097i
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Amylin receptor · full Obesity pipeline
eloralintide
Developed by Eli Lilly
NCT06230523 · Phase 2 · completed
Randomized, double-blind, placebo-controlled phase 2 in obesity and overweight (263 participants). Week-48 body-weight reductions ranged from 9.4% to 20.1% across eloralintide doses versus 0.4% on placebo, a separation many times larger than the reported error margins; percent change in body weight is the accepted registrational endpoint in obesity.
Next expected readout: December 2026 · NCT07738614 (registry estimate)
MET-097i
Developed by Pfizer
NCT06712836 · Phase 2 · completed
The study randomized 239 participants to MET097 or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical outcome of body-weight change at Week 28. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: January 2027 · NCT07508241 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: eloralintide's landscape · MET-097i's landscape